Analyst Research

Report Title Price
Thomson Reuters Stock Report - DR REDDYS LABORATORIES LIMITED (DRREDDY-IN)
Provider: Thomson Reuters Stock Report
$25.00
Buy
ValuEngine Detailed Valuation Report for RDY
Provider: ValuEngine, Inc.
$127.00
Buy
Wright Investors Service Comprehensive Report for Dr Reddys Laboratories Limited
Provider: Wright Reports
$460.00
Buy
Dr. Reddy's Labs ADS
Provider: S&P Capital IQ – STARS Reports
$115.00
Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Dr.Reddy's Laboratories Ltd Launches Recommended Public Cash Offer For All Issued And Outstanding Ordinary Shares Of OctoPlus NV


Thursday, 13 Dec 2012 10:24pm EST 

Dr.Reddy's Laboratories Ltd, together with its subsidiaries, announced that it has launched the recommended public offer to acquire all the issued and outstanding shares of OctoPlus NV at an offer price of EUR0.52 (cum dividend) per share. The Offer Period commences on December 14, 2012 at 09:00 CET and ends on February 08, 2013 at 18:00 CET, unless extended. 

Latest Developments for Dr.Reddy's Laboratories Ltd

Latest Key Developments in Pharmaceuticals

Related Company News

Company Quote

Dr.Reddy's Laboratories Ltd
(RDY.N)
37.32
-0.17 -0.45%
23 May 2013